AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Beyfortus (nirsevimab by Year
Beyfortus (nirsevimab — direct product sales) — Worldwide YoY actual (%) (%)
AstraZeneca Beyfortus (nirsevimab: -12.0% in FY2025.
Latest, FY2025
-12.0%
Period ended Dec 31, 2025
Change on a year earlier
–
History
1 years
Since FY2025
Sources
1
Form 6-K FY2025Q4 Earnings Release
Where the FY2025 figure comes from
“|| Beyfortus | 281 | (12) | (12) | 184 | (21) | - | - | - | 94 | 12 | 12 | 3 | 58 | 53”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Beyfortus (nirsevimab — direct product sales) — Worldwide YoY actual (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -12.0% | – | Form 6-K FY2025Q4 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Beyfortus (nirsevimab (%), annual FY2025–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-beyfortus-world-act-yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.